Zun-Ping Ke

Dr. Zun-Ping Ke

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2018 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
LWLei Wang
Lei Wang
JXJing‐Wen Xia
Jing‐Wen Xia
ZKZun-Ping Ke
Zun-Ping Ke
BZBing‐Hong Zhang
Bing‐Hong Zhang

1 January 2018 in Chemico-Biological Interactions
Verified
Journal Article
Closed access
AGAi-Mei Gao
Ai-Mei Gao
XZXiao-Yu Zhang
Xiao-Yu Zhang
JHJuan-Ni Hu
Juan-Ni Hu
ZKZun-Ping Ke
Zun-Ping Ke

30 May 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
AGAimei Gao
Aimei Gao
XZXiao-Yu Zhang
Xiao-Yu Zhang
ZKZun-Ping Ke
Zun-Ping Ke
Apigenin sensitizes BEL-7402/ADM cells to doxorubicin through inhibiting miR-101/Nrf2 pathway Apigenin sensitizes BEL-7402/ADM cells to doxorubicin through inhibiting miR-101/Nrf2 pathway

11 December 2017 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
SQSong‐Bai Qin
Song‐Bai Qin
DPDa‐Yan Peng
Da‐Yan Peng
JLJing‐Min Lu
Jing‐Min Lu
ZKZun-Ping Ke
Zun-Ping Ke

6 September 2018 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
JLJie Liu
Jie Liu
GHGuang‐Qing Huang
Guang‐Qing Huang
ZKZun-Ping Ke
Zun-Ping Ke

17 April 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
YXYong Xu
Yong Xu
BZBo Zhang
Bo Zhang
DXDa Xie
Da Xie
YHYu Hu
Yu Hu
HLHai-Lun Li
Hai-Lun Li
DZDonghui Zheng
Donghui Zheng
Nanoparticle-mediated dual delivery of resveratrol and DAP5 ameliorates kidney ischemia/reperfusion injury by inhibiting cell apoptosis and inflammation